PE20230301A1 - Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion - Google Patents

Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion

Info

Publication number
PE20230301A1
PE20230301A1 PE2022001743A PE2022001743A PE20230301A1 PE 20230301 A1 PE20230301 A1 PE 20230301A1 PE 2022001743 A PE2022001743 A PE 2022001743A PE 2022001743 A PE2022001743 A PE 2022001743A PE 20230301 A1 PE20230301 A1 PE 20230301A1
Authority
PE
Peru
Prior art keywords
polypeptides
infection
treat
development
limit
Prior art date
Application number
PE2022001743A
Other languages
English (en)
Spanish (es)
Inventor
Neil P King
David Veesler
Carl Walkey
Alexandra C Walls
Jing Yang Wang
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of PE20230301A1 publication Critical patent/PE20230301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PE2022001743A 2020-02-14 2021-02-12 Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion PE20230301A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
US202063046159P 2020-06-30 2020-06-30
US202063064235P 2020-08-11 2020-08-11
PCT/US2021/017799 WO2021163438A1 (en) 2020-02-14 2021-02-12 Polypeptides, compositions, and their use to treat or limit development of an infection

Publications (1)

Publication Number Publication Date
PE20230301A1 true PE20230301A1 (es) 2023-02-13

Family

ID=74873805

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001743A PE20230301A1 (es) 2020-02-14 2021-02-12 Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion

Country Status (13)

Country Link
US (1) US20240277831A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103230A1 (cg-RX-API-DMAC7.html)
JP (1) JP7897796B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220142472A (cg-RX-API-DMAC7.html)
CN (1) CN116096404A (cg-RX-API-DMAC7.html)
AU (1) AU2021221139A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016220A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167318A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011467A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022009860A (cg-RX-API-DMAC7.html)
PE (1) PE20230301A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552099A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021163438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US11192940B2 (en) 2020-04-10 2021-12-07 Adagio Therapeutics, Inc. Compounds specific to coronavirus S protein and uses thereof
US20220016268A1 (en) * 2020-07-17 2022-01-20 Tonix Pharmaceuticals Holding Corp. Skin-based testing for detection of cell-mediated immune responses to sars-cov-2
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
US20220324918A1 (en) * 2021-03-30 2022-10-13 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF
WO2023034991A1 (en) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Mrna vaccine formulations and methods of using the same
WO2023039540A2 (en) * 2021-09-10 2023-03-16 Jacobs Technion-Cornell Institute Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions
KR102621026B1 (ko) * 2021-10-15 2024-01-09 에스케이바이오사이언스(주) 단백질의 정제방법
KR102527221B1 (ko) * 2021-10-15 2023-05-02 에스케이바이오사이언스 주식회사 단백질의 정제방법
KR102524839B1 (ko) * 2021-11-04 2023-04-25 에스케이바이오사이언스(주) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
US20250000968A1 (en) * 2021-11-12 2025-01-02 The United States of America, as represented by the Secretary,Department of Health and Human Service Sars-cov-2 spike fused to a hepatitis b surface antigen
WO2023122257A2 (en) * 2021-12-22 2023-06-29 La Jolla Institute For Immunology Coronavirus spike glycoprotein with improved expression and stability
CN114656571B (zh) * 2022-02-18 2024-07-16 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用
US20240207389A1 (en) * 2022-04-27 2024-06-27 Northwestern University Methods for improving covid vaccine immunogenicity
KR102689037B1 (ko) * 2022-07-12 2024-07-30 에스케이바이오사이언스 주식회사 SARS-CoV-2 백신 부스터 조성물
KR20250084945A (ko) * 2022-10-05 2025-06-11 유니버시티 오브 워싱턴 범사르베코바이러스 나노입자 백신
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016639A2 (en) * 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
US10248758B2 (en) * 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
WO2015080973A1 (en) * 2013-11-26 2015-06-04 Baylor College Of Medicine A novel sars immunogenic composition
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2017046801A1 (en) * 2015-09-17 2017-03-23 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
WO2018175560A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
EP3606942B1 (en) * 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN112088014B (zh) * 2018-02-28 2026-03-24 华盛顿大学 自组装纳米结构疫苗

Also Published As

Publication number Publication date
EP4103230A1 (en) 2022-12-21
WO2021163438A1 (en) 2021-08-19
MX2022009860A (es) 2022-11-07
CO2022011467A2 (es) 2022-10-31
KR20220142472A (ko) 2022-10-21
BR112022016220A2 (pt) 2022-10-25
JP2023513720A (ja) 2023-04-03
JP7897796B2 (ja) 2026-07-30
PH12022552099A1 (en) 2024-01-29
CA3167318A1 (en) 2021-08-19
CN116096404A (zh) 2023-05-09
US20240277831A1 (en) 2024-08-22
AU2021221139A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CO2022011467A2 (es) Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección
ES2562157T3 (es) Vacuna multiepitópica contra los cánceres asociados con Her2/neu
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
PE20130588A1 (es) Hepcidina, antagonistas de la hepcidina y metodos de uso
PE20251185A1 (es) Proteinas de union condicionalmente activadas restringidas
JOP20240283A1 (ar) تركيبة منظف الشعر وفروة الرأس لإزالة السموم، طرق استخدامها واستخداماتها
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
KR960703942A (ko) 사람 융모막 고나도트로핀의 항원성을 갖는 화합물(Compounds having the antigenicity of hCG)
CY1113218T1 (el) Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
BRPI9911389B8 (pt) peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo
AR008588A1 (es) Molecula de acido nucleico aislada que hibridiza con un gen de saliva de pulga, proteina aislada codificada por dicha molecula, composicion terapeuticapara tratar la dermatitis alergica, kit de ensayo para determinar dicha dermatitis, molecula, virus y celula recombinantes, y anticuerpo aislado
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
Mitchell et al. Localisation of light chain and actin binding sites on myosin
AR035387A1 (es) Molecula de adn que codifica una udp-glucosa: aglicon-glucosiltransferasa, udp-glucosa: aglicon-glucosiltransferasa, metodo para el aislamiento de una molecula de adnc que codifica una udp-glucosa: aglicon-glucosiltransferasa, metodo para producir udp-glucosa: aglicon-glucosiltransferasa recombinant
GT199800032A (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas.
AR125379A1 (es) Un fab anti-tslp con estabilidad mejorada
PE20231442A1 (es) Proteinas actrii y sus usos
Eckerskorn et al. In the uncoupling protein from brown adipose tissue the C-terminus protrudes to the c-side of the membrane as shown by tryptic cleavage
CY1105683T1 (el) Ενεργο συζυγες ακανθοχοιρικης πρωτεϊνης, μεθοδος για την παρασκευη και χρηση αυτου
AR070177A1 (es) COMPOSICIONES BACTERIANAS QUE COMPRENDEN PROTEíNAS PERTENECIENTES AL GRUPO DE RECEPTORES DE RECONOCIMIENTO DE PATRONES (PRR) QUE PRESENTAN UN DOMINIO DE REPETICIoN DE LEUCINA (RRL)
ECSP22064620A (es) COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2
AR129441A1 (es) Péptidos y métodos para el tratamiento del dolor
AR132053A1 (es) Composiciones para su uso en el tratamiento de clamidia
AR129864A1 (es) Péptidos y métodos para uso en tratar el dolor
BR112023017163A2 (pt) Proteína transportadora para antígeno peptídico